The miscellaneous works of Tobias Smollett, M. D. : with memoirs of his life and writings /

Mode of access: Internet.

Die Fortpflanzung und Vermehrung des Menschen aus dem Gesichtspunkte der Physiologie und Bevölkerungslehre betrachtet.

Mode of access: Internet.

Ten years in the ranks, U. S. army,

"Service ... on the frontier and during the Civil war," 1854-1865.

Studies from the Physiological Laboratory of Owens College, Manchester

Editor: 1891- , W. Stirling.

Don John of Austria,

Mode of access: Internet.

William De Morgan and his wife,

Mode of access: Internet.

A manual of human physiology, including histology and microscopical anatomy, with special reference to the requirements of practical medicine

Translation of: Lehrbuch der physiologie des Menschen.

Remarks on thorough draining and deep ploughing.

Mode of access: Internet.

A painter of dreams, and other biographical studies,

A Georgian scrap-book.--A friend of freedom [William Bosville]--An autocrat [4th Earl of Albemarle]--A dupe of destiny [Elizabeth Patterson Bonaparte]--A favourite of destiny [Mary Caton, marchioness of Wellesley]--A painter of realities [J. F. Herring]--A painter of dreams, the life of Roddam Spencer Stanhope.

The letter-bag of Lady Elizabeth Spencer-Stanhope /

Sequel and conclusion to the author's Coke of Norfolk and his friends, 1906; and Annals of a Yorkshire house, 1911.

Old Drury Lane; fifty years' recollections of author, actor, and manager,

Mode of access: Internet.

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX (TM) adjuvant in women with cervical intraepithelial neoplasia

Purpose: Persistent infection of cervical epithelium with high risk human papillomavirus (HPV) results in cervical intraepithelial neoplasia (CIN) from which squamous cancer of the cervix can arise. A study was undertaken to evaluate the safety and immunogenicity of an HPV 16 immunotherapeutic consisting of a mixture of HPV16 E6E7 fusion protein and ISCOMATRIX(TM) adjuvant (HPV16 Immunotherapeutic) for patients with CIN. Experimental design: Patients with CIN (n = 3 1) were recruited to a randomised blinded placebo controlled dose ranging study of immunotherapy. Results: Immunotherapy was well tolerated. Immunised subjects developed HPV16 E6E7 specific immunity. Antibody, delayed type hypersensitivity, in vitro cytokine release, and CD8 T cell responses to E6 and E7 proteins were each significantly greater in the immunised subjects than in placebo recipients. Loss of HPV16 DNA from the cervix was observed in some vaccine and placebo recipients. Conclusions : The HPV16 Immunotherapeutic comprising HPV16E6E7 fusion protein and ISCOMATRIX(TM) adjuvant is safe and induces vaccine antigen specific cell mediated immunity. (C) 2004 Elsevier Ltd. All rights reserved.

ISCOMATRIX (TM) adjuvant: An adjuvant suitable for use in anticancer vaccines

Human Papillomavirus type 16 (HPV16) E6 and E7 oncoproteins are associated with cervical cancer development and progression and can therefore be used as target antigens for cancer immunotherapy. In this study we evaluated the immunogenicity in mice, of different vaccine formulations using recombinant HPV16 derived E6E7 or E7GST fusion proteins. When co-administered with ISCOMATRIX(TM) adjuvant, these E6E7 proteins consistently induced E7 specific CTL, in vivo tumor protection, antibody and DTH responses. ISCOMATRIX(TM) adjuvant has been developed for use in the formulation of novel human vaccines and has been evaluated for safety and toxicity in human trials. A formulation containing aluminum hydroxide (Al(OH)(3)) gave a lesser degree of E7 specific antibody, and no local E7 specific CTL response but similar DTH and tumor protection. These findings demonstrate the potential of ISCOMATRIX(TM) adjuvant to stimulate both cellular and humoral immune responses to endogenously processed target antigens, and hence is the preferred adjuvant when CTL responses are desirable. (C) 2004 Elsevier Ltd. All rights reserved.

Journey of net blotch: From pathotype diversity to useful resistance in barley

Studies on variation, occurrence and distribution of virulence in Pyrenophora teres f. teres are essential to identify effective sources of resistance for net type net blotch. Disease surveys suggested two different stains are prevalent in Western Australia and 13 in all around Australia. Sixty nine barley lines from different breeding groups in Australia and elsewhere were tested against most prevalent pathotypes. Majority of lines have partial to complete resistance while some have elite resistances to net type net blotch. Four lines out of 69 were chosen for further studies. These four lines: WA 4794 (103 IBON 91), Pompadour, CI 9214, and WPG 8412-9-2-1 were highly diverse and resistant to most of the isolates, and were crossed with Stirling-a highly adaptive but susceptible cultivar. Doubled haploids, F2s, and resistant x resistant crosses were studied against five prevalent isolates. Four genes from WA 4794 (all dominant), three (two dominant and one recessive) from Pompadour, five (two dominant and three recessive) from CI 9214, and two (one dominant and one recessive) from WPG 8412-9-2-1 were identified. In total, 11 different genes were operative against P. teres f. teres isolates. Molecular work is initiated to develop markers which would aid screening of the breeding populations for these resistances.